600196 复星医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入30,911,8890.69%41,399,54043,951,54739,011,18430,306,981
减:营业总成本29,362,813-3.04%41,284,07741,346,26437,093,26628,594,719
    其中:营业成本15,889,6000.70%21,595,30923,169,69020,229,78513,733,529
               财务费用854,56513.03%984,323647,403464,022724,273
               资产减值损失(40,947)-85.92%(219,742)(272,488)(829,873)(148,254)
公允价值变动收益(106,246)-113.18%(427,380)(2,498,368)352,299578,657
投资收益1,498,763-31.33%3,501,9934,377,8434,623,8262,283,981
    其中:对联营企业和合营企业的投资收益1,214,652-18.80%2,184,8491,835,1461,789,1371,580,335
营业利润3,107,589-7.02%3,307,5084,656,6566,302,5684,721,145
利润总额3,071,566-6.71%3,264,5684,574,3826,042,6714,677,844
减:所得税费用553,048-13.40%369,504626,9171,066,401737,865
净利润2,518,518-5.10%2,895,0633,947,4644,976,2693,939,980
减:非控股权益507,87536.99%508,798216,660247,559277,167
股东净利润2,010,642-11.93%2,386,2663,730,8054,728,7113,662,813

市场价值指针
每股收益 (元) *0.750-12.79%0.8901.4301.8501.430
每股派息 (元) *----0.2700.4200.5600.430
每股净资产 (元) *17.7003.01%17.11016.68415.29214.435
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容